Drugs aimed at ERBB2, FCGR3A, and FLT3 are primarily used in treating various cancers and benign tumors, while ALDH2 is targeted in therapies for a range of systemic diseases, notably cancer and substance dependence. The gene discussed is FLT3; the disease is benign neoplasm.